Windtree Therapeutics (WINT) Stock Overview
A biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
WINT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Windtree Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.10 |
| 52 Week High | US$37.42 |
| 52 Week Low | US$0.058 |
| Beta | 0.51 |
| 1 Month Change | 32.41% |
| 3 Month Change | -82.02% |
| 1 Year Change | -99.71% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)
Dec 06Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions
Jul 06Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable
Jun 09
Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?
Feb 09Shareholder Returns
| WINT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.8% | 3.1% | 0.5% |
| 1Y | -99.7% | 3.9% | 20.1% |
Return vs Industry: WINT underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: WINT underperformed the US Market which returned 20% over the past year.
Price Volatility
| WINT volatility | |
|---|---|
| WINT Average Weekly Movement | 34.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: WINT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: WINT's weekly volatility has increased from 26% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 14 | Jed Latkin | windtreetx.com |
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure.
Windtree Therapeutics, Inc. Fundamentals Summary
| WINT fundamental statistics | |
|---|---|
| Market cap | US$3.52m |
| Earnings (TTM) | -US$23.64m |
| Revenue (TTM) | n/a |
Is WINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WINT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$23.64m |
| Earnings | -US$23.64m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 215.8% |
How did WINT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 09:22 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Windtree Therapeutics, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leland Gershell | Oppenheimer & Co. Inc. |
| David Amsellem | Piper Sandler Companies |
| David Moskowitz | Roth Capital Partners |